NCT00144521View on ClinicalTrials.gov

Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)

PHASE3CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

August 31, 2004

Study Completion Date

April 30, 2006

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MRA(Tocilizumab)

8mg/kg/4week(i.v.)for 24 weeks

DRUG

MRA placebo

0mg/kg/4week(i.v.) for 24 weeks

DRUG

MTX

8mg/week(p.o.) for 24 weeks

DRUG

MTX placebo

0mg/week(p.o.) for 24 weeks

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY

NCT00144521 - Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA) | Biotech Hunter | Biotech Hunter